{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:49:08Z","timestamp":1792784948744,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U10HL069294"],"award-info":[{"award-number":["U10HL069294"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Eastern Cooperative Oncology Group","award":["CA180820"],"award-info":[{"award-number":["CA180820"]}],"id":[{"id":"https:\/\/ror.org\/01hfgte37","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Eastern Cooperative Oncology Group","award":["CA180853"],"award-info":[{"award-number":["CA180853"]}],"id":[{"id":"https:\/\/ror.org\/01hfgte37","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Eastern Cooperative Oncology Group","award":["CA 180799"],"award-info":[{"award-number":["CA 180799"]}],"id":[{"id":"https:\/\/ror.org\/01hfgte37","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Southwest Oncology Group NCTN","award":["U10 CA180888"],"award-info":[{"award-number":["U10 CA180888"]}],"id":[{"id":"https:\/\/ror.org\/05n6zrm60","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung and Blood Institute","doi-asserted-by":"crossref","award":["U10HL069294"],"award-info":[{"award-number":["U10HL069294"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006316","name":"Alliance for Clinical Trials in Oncology","doi-asserted-by":"crossref","award":["U10CA180821 and U10CA180882"],"award-info":[{"award-number":["U10CA180821 and U10CA180882"]}],"id":[{"id":"10.13039\/100006316","id-type":"DOI","asserted-by":"crossref"}]},{"name":"ECOG-ACRIN Cancer Research Group","award":["CA 180820"],"award-info":[{"award-number":["CA 180820"]}],"id":[{"id":"https:\/\/ror.org\/00d3km654","id-type":"ROR","asserted-by":"crossref"}]},{"name":"ECOG-ACRIN Cancer Research Group","award":["CA 180853"],"award-info":[{"award-number":["CA 180853"]}],"id":[{"id":"https:\/\/ror.org\/00d3km654","id-type":"ROR","asserted-by":"crossref"}]},{"name":"ECOG-ACRIN Cancer Research Group","award":["CA 180799"],"award-info":[{"award-number":["CA 180799"]}],"id":[{"id":"https:\/\/ror.org\/00d3km654","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Southwest Oncology Group","award":["U10CA180888"],"award-info":[{"award-number":["U10CA180888"]}],"id":[{"id":"https:\/\/ror.org\/05n6zrm60","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.bbmt.2016.04.014","type":"journal-article","created":{"date-parts":[[2016,4,30]],"date-time":"2016-04-30T11:16:39Z","timestamp":1462014999000},"page":"1440-1448","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network"],"prefix":"10.1016","volume":"22","author":[{"given":"Ginna G.","family":"Laport","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"Logan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Bachanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitra","family":"Hosing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Fenske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Devine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Auayporn","family":"Nademanee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Gersten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillard M.","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcie L.","family":"Riches","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2016.04.014_bib1","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A\u00a0clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project","volume":"89","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.04.014_bib2","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.04.014_bib3","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma","volume":"26","author":"Marcus","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.04.014_bib4","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/ajh.23674","article-title":"Follicular lymphoma: 2014 update on diagnosis and management","volume":"89","author":"Freedman","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2016.04.014_bib5","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1002\/cncr.28243","article-title":"Stem cell transplantation for follicular lymphoma relapsed\/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project","volume":"119","author":"Evens","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2016.04.014_bib6","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/bjh.12741","article-title":"Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result in durable remissions, irrespective of prior rituximab exposure","volume":"165","author":"Kothari","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2016.04.014_bib7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.bbmt.2007.06.016","article-title":"Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and Follicular International Prognostic Index","volume":"14","author":"Vose","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.04.014_bib8","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1182\/blood-2003-04-1205","article-title":"Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma","volume":"102","author":"van Besien","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.04.014_bib9","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/sj.bmt.1703891","article-title":"An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation","volume":"31","author":"Peniket","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.04.014_bib10","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1200\/JCO.2009.26.9100","article-title":"T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma","volume":"28","author":"Thomson","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.04.014_bib11","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.bbmt.2011.01.016","article-title":"Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901","volume":"17","author":"Shea","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.04.014_bib12","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.3324\/haematol.2009.017608","article-title":"Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials","volume":"95","author":"Pinana","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2016.04.014_bib13","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1200\/JCO.2007.11.5477","article-title":"Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma","volume":"26","author":"Rezvani","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.04.014_bib14","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.1182\/blood-2012-03-417808","article-title":"Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results","volume":"119","author":"Khouri","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.04.014_bib15","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/bmt.2013.83","article-title":"The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT","volume":"48","author":"Robinson","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.04.014_bib16","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.bbmt.2010.11.004","article-title":"Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response","volume":"17","author":"Tomblyn","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.04.014_bib17","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1182\/blood-2008-01-136242","article-title":"Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab","volume":"111","author":"Khouri","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.04.014_bib18","series-title":"WHO classification of tumours of hematopoietic and lymphoid tissues. 4th ed","first-page":"439","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.bbmt.2016.04.014_bib19","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A\u00a0revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.04.014_bib20","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.04.014_bib21","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.04.014_bib22","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.04.014_bib23","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/sj.bmt.1700672","article-title":"Quality of life measurement in bone marrow transplantation: development of the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) scale","volume":"19","author":"McQuellon","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.04.014_bib24","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"10.1016\/j.bbmt.2016.04.014_bib25","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J\u00a0Am Stat Assn"},{"key":"10.1016\/j.bbmt.2016.04.014_bib26","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/(SICI)1097-0258(19970430)16:8<901::AID-SIM543>3.0.CO;2-M","article-title":"Non-parametric inference for cumulative incidence functions in competing risks studies","volume":"16","author":"Lin","year":"1997","journal-title":"Stat Med"},{"key":"10.1016\/j.bbmt.2016.04.014_bib27","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1023\/A:1008416911099","article-title":"Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma","volume":"9","author":"Berinstein","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2016.04.014_bib28","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1023\/A:1008265313133","article-title":"Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group","volume":"9","author":"Tobinai","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2016.04.014_bib29","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.bbmt.2014.11.676","article-title":"Rabbit anti-T cell globulin in allogeneic hematopoietic cell transplantation","volume":"21","author":"Storek","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.04.014_bib30","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1182\/blood-2013-04-495895","article-title":"Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial","volume":"122","author":"Cutler","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.04.014_bib31","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood-2006-01-0233","article-title":"Rituximab for steroid-refractory chronic graft-versus-host disease","volume":"108","author":"Cutler","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.04.014_bib32","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.bbmt.2009.04.003","article-title":"Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis","volume":"15","author":"Kharfan-Dabaja","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.04.014_bib33","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.bbmt.2006.06.013","article-title":"Rituximab responsive refractory acute graft-versus-host disease","volume":"12","author":"Kamble","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.04.014_bib34","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.bbmt.2007.11.004","article-title":"Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning","volume":"14","author":"Hari","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.04.014_bib35","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/j.1365-2141.2009.07905.x","article-title":"Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"147","author":"Avivi","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2016.04.014_bib36","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/ajh.23919","article-title":"Autologous stem cell transplantation with in\u00a0vivo purged progenitor cells shows long-term efficacy in relapsed\/refractory follicular lymphoma","volume":"90","author":"Arcaini","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2016.04.014_bib37","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1200\/JCO.2012.47.1862","article-title":"Rituximab purging and\/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation","volume":"31","author":"Pettengell","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.04.014_bib38","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1200\/JCO.2006.09.8327","article-title":"Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up","volume":"25","author":"Rohatiner","year":"2007","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879116300337?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879116300337?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:55:36Z","timestamp":1761058536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879116300337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S1083879116300337"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2016.04.014","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2016.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}